No­vo Nordisk to re­strict starter dose sup­ply for weight loss drug We­govy

Faced with “all-time high lev­els” of new pa­tients start­ing No­vo Nordisk’s GLP-1 prod­ucts, the com­pa­ny is tem­porar­i­ly re­strict­ing its sup­ply of low­er We­govy dose strengths to “safe­guard con­ti­nu­ity of care,” ac­cord­ing to EVP of North Amer­i­ca op­er­a­tions Doug Lan­ga.

The com­pa­ny will on­ly be able to sup­ply a lim­it­ed amount of 0.25 mg, 0.5 mg and 1 mg dos­es to whole­salers for dis­tri­b­u­tion to re­tail phar­ma­cies which “will not meet an­tic­i­pat­ed pa­tient de­mand,” a spokesper­son told End­points News. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER